N-Propargylamine protects SH-SY5Y cells from apoptosis induced by an endogenous neurotoxin, N-methyl(R)salsolinol, through stabilization of mitochondrial membrane and induction of anti-apoptotic Bcl-2

Journal of Neural Transmission

Volumn 113, Issue 1, 2006, Pages 21-32

  Yi, H ^a   Maruyama, W ^b   Akao, Y ^a   Takahashi, T ^c   Iwasa, K ^d   Youdim, M B H ^e   Naoi, M ^a  

^a GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^b NATIONAL CENTER FOR GERIATRICS AND GERONTOLOGY   (Japan)

^c Aichi Konan College   (Japan)

^d KOBE PHARMACEUTICAL UNIVERSITY   (Japan)

^e TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Apoptosis; Bcl 2; Mitochondrial membrane potential; Monoamine oxidase inhibitor; Neuroprotection; Propargylamine

Indexed keywords

ALDEHYDE DERIVATIVE; AMINE OXIDASE (FLAVIN CONTAINING); MONOAMINE OXIDASE INHIBITOR; N METHYLPROPARGYLAMINE; N METHYLSALSOLINOL; N PROPARGYLAMINE; NEUROPROTECTIVE AGENT; NEUROTOXIN; PROPIOALDEHYDE; PROTEIN BCL 2; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DEGENERATIVE DISEASE; ENZYME INHIBITION; HUMAN; HUMAN CELL; MEMBRANE POTENTIAL; MITOCHONDRIAL MEMBRANE; NEUROPROTECTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; STATISTICAL SIGNIFICANCE;

APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MITOCHONDRIA; MITOCHONDRIAL MEMBRANES; NEUROPROTECTIVE AGENTS; PARGYLINE; PROPYLAMINES; PROTO-ONCOGENE PROTEINS C-BCL-2; SALSOLINE ALKALOIDS; TETRAHYDROISOQUINOLINES; TUMOR CELLS, CULTURED;

EID: 29244431681     PISSN: 03009564     EISSN: 14351463     Source Type: Journal    
DOI: 10.1007/s00702-005-0299-z     Document Type: Article

References (44)

1. Y Akao W Maruyama S Shimizu H Yi Y Nakagawa M Shamoto-Nagai MBH Youdim Y Tsujimoto M Naoi 2002a Mitochondrial permeability transition mediates apoptosis induced by N-methyl(R)salsolinol, an endogenous neurotoxin, and is inhibited by Bcl-2 and rasagiline, N-propargyl-1(R)-aminoindan. J Neurochem 82 913 923
2. Y Akao W Maruyama H Yi M Shamoto-Nagai MBH Youdim M Naoi 2002b An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells. Neurosci Lett 326 10510 10518
3. O Bar-Am A Yogev-Falach T Amit Y Sagi MBH Youdim 2004 Regulation of protein kinase C by the anti-parkinson drug, MAO-B inhibitor rasagiline and its derivatives, in vivo. J Neurochem 89 1119 1125
4. MM Bradford 1976 A rapid and sensitive method for the quantitation of microgram quantities of protein using the principle of protein dye binding. Anal Biochem 72 248 254
5. MC Carrillo C Minami K Kitani W Maruyama K Ohashi T Yamamoto M Naoi S Kanai MB Youdim 2000 Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci 67 577 585
6. EG DeMaster FN Shirota HT Nagasawa 1981 Role of propiolaldehyde and other metabolites in the pargyline inhibition of rat liver aldehyde dehydrogenase. Biochem Pharmacol 35 1481 1489
7. S Desagher A Osen-Sand A Nichols R Eskes S Montessuit S Lauper K Maundrell B Antonsson J-C Martinou 1999 Bid-induced conformational change of Bax is responsible for mitochondrial cytochrome c release during apoptosis. J Cell Biol 144 891 901
8. A Eckert B Steiner C Marques S Leutz H Roming C Haass WE Muller 2001 Elevated vulnerability to oxidative stress-induced cell death and activation of caspase-3 by the Swedish amyloid precursor protein mutation. J Neurosci Res 64 183 192
9. JPM Finberg T Takeshima JM Johnson JW Commissiong 1998 Increased survival of dopaminergic neurons by rasagiline, a monoamine oxidase B inhibitor. NeuroReport 9 701 707
10. J Knoll Z Ecsery K Magyar E Satory 1978 Novel (-)deprenyl-derived selective inhibitors of B-type monoamine oxidase. The relation of structure to their action. Biochem Pharmacol 27 1739 1747
11. M Kraml 1965 A rapid microfluorometric determination of monoamine oxidase. Biochem Pharmacol 14 1684 1686
12. K Magyar B Szende J Lengyel K Tekes 1996 The pharmacology of B-type selective monoamine oxidase inhibitors: milestones in (-)-deprenyl research. J Neural Transm (Suppl) 48 29 43
13. W Maruyama M Naoi 1999 Neuroprotection by (-)-deprenyl and related compounds. Mech Ageing Dev 111 189 200
14. W Maruyama Y Akao MBH Youdim M Naoi 2000 Neurotoxins induce apoptosis in dopamine neurons: protection by N-propargylamine-1(R)- and (S)-aminoindan, rasagiline and TV1022. J Neural Transm (Suppl) 60 171 186
15. W Maruyama Y Akao MBH Youdim BA Davis M Naoi 2001a Transfection-forced Bcl-2 overexpression and anti-Parkinson drug, rasagiline, prevent nuclear translocation of glyceraldehydes-3-phosphate dehydrogenase induced by an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol. J Neurochem 78 727 735
16. W Maruyama AA Boulton BA Davis P Dostert M Naoi 2001b Enantio-specific induction of apoptosis by an endogenous neurotoxin N-methyl(R)salsolinol, in dopaminergic SH-SY5Y cells: suppression of apoptosis by N-(2-heptyl)-N- methylpropargylamine. J Neural Transm 108 11 24
17. W Maruyama MBH Youdim M Naoi 2001c Antiapoptotic properties of rasagiline, N-propargylamine-1(R)-aminoindan, and its optical (S)-isomer, TV1022. Ann NY Acad Sci 939 320 329
18. W Maruyama T Takahashi MBH Youdim M Naoi 2002 The anti-Parkinson drug, rasagiline, prevents apoptotic DNA damage induced by peroxynitrite in human dopaminergic neuroblastoma SH-SY5Y cells. J Neural Transm 109 467 481
19. W Maruyama M Weinstock MBH Youdim M Nagai M Naoi 2003 Anti-apoptotic action of anti-Alzheimer drug, TV3326 [(N-propargyl)-(3R)-aminoindan-5-yl]-ethyl methyl carbamate, a novel cholinesterase-monoamine inhibitor. Neurosci Lett 341 233 236
20. W Maruyama A Nitta M Shamoto-Nagai Y Hirata Y Akao M Youdim S Furukawa T Nabeshima M Naoi 2004 N-Propargyl-1(R)-aminoindan, rasagiline, increases glial cell line-derived neurotrophic factor (GDNF) in neuroblastoma SH-SY5Y cells through activation of NF-κB transcription factor. Neurochem Int 44 393 400
21. C Mytilineou PM Radcliffe CW Olanow 1997 L-(-)-Desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitoxicity in vitro. J Neurochem 68 434 435
22. J Nagy JL Salach 1981 Identity of the active site flavin-peptide fragments from the human "A"-form and the bovine "B"-form of monoamine oxidase. Arch Biochem Biophys 208 388 394
23. M Naoi W Maruyama 2001 Future of neuroprotection in Parkinson's disease. Parkinsonism Relat Disord 8 139 145
24. M Naoi W Maruyama Y Akao H Yi 2002a Mitochondria determine the survival and death in apoptosis induced by an endogenous neurotoxin, N-methyl(R) salsolinol, and neuroprotection by propargylamines. J Neural Transm 109 607 621
25. M Naoi W Maruyama Y Akao H Yi 2002b Dopamine-derived endogenous N-methyl-(R)-salsolinol. Its role in Parkinson's disease. Neurotoxicol Teratol 24 579 591
26. M Naoi W Maruyama MB Youdim P Yu AA Boulton 2003 Anti-apoptotic function of propargylamine inhibitors of type-B monoamine oxidase. Inflammopharmacology 11 175 181
27. Parkinson Study Group 2002 A controlled trial of rasagiline in early Parkinson disease. Arch Neurol 59 1037 1943
28. Parkinson Study Group 2004 A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Arch Neurol 61 561 566
29. BM Ravina SC Fagan RG Hart CA Hovinga DD Murphy TM Dawson JR Marler 2003 Neuroprotective agents for clinical trials in Parkinson's disease. A systematic assessment. Neurol 60 1234 1240
30. P Riederer L Lachenmayer 2003 Selegiline's neuroprotective capacity revisited. J Neural Transm 110 1273 1278
31. FN Shirota EG DeMaster HT Nagasawa 1979 Propioladehyde, a pargyline metabolite that irreversibly inhibits aldehyde dehydrogenase. Isolation from a hepatic microsomal system. J Med Chem 22 463 464
32. WG Tatton WYL Ju DP Holland C Tai M Kwan 1994 (-)-Deprenyl reduces PC12 cell apoptosis by inducing new protein synthesis. J Neurochem 63 1572 1575
33. S Teitel J O'Brien A Brossi 1972 Alkaloids in mammalian tissue II. Synthesis of (+) and (-) substituted 6,7-dihydroxy-1,2,3,4- tetrahydroisoquinolines. J Med Chem 15 845 846
34. Y Tsujimoto S Shimizu 2000 Bcl-2 family: life-or-death switch. FEBS Lett 466 6 10
35. M Vila S Przedborski 2003 Targeting programmed cell death in neurodegenerative diseases. Nat Rev Neurosci 4 365 375
36. O Weinreb O Bar-Am T Amit O Chillag-Talmor MBH Youdim 2004 Neuroprotection via pro-survival PKC isoforms associated with Bcl-2 family members. FASEB J 18 2033 2043
37. M Yogev-Falach T Amit O Bar-Am M Weinstock MB Youdim 2002 Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J 16 1674 1676
38. M Yogev-Falach T Amit O Bar-Am MBH Youdim 2003 The importance of propargylamine moiety in the ant-Parkinson drug rasagiline and its derivatives for MAPK-dependent amyloid precursor protein processing. FASEB J 17 2325 2327
39. MBH Youdim A Gross JPM Finberg 2001a Rasagiline [N-propargyl-1R(+)- aminoindan], a selective and potent inhibitor of mitochondrial monoamine oxidase B. Br J Pharmacol 132 500 506
40. MB Youdim A Wadia W Tatton M Weinstock 2001b The anti-Parkinson drug rasagiline and its cholinesterase inhibitor derivatives exert neuroprotection unrelated to MAO inhibition in cell culture and in vivo. Ann NY Acad Sci 939 450 458
41. MBH Youdim T Amit M Falach-Yogev OB Am W Maruyama M Naoi 2003 The essentiality of Bcl-2, PKC and proteasome-ubiquitin complex activations in the neuroprotective-antiapoptotic action of the anti-Parkinson drug, rasagiline. Biochem Pharmacol 66 1635 1641
42. PH Yu BA Davis AA Boulton 1992 Aliphatic propargylamines: potent, selective, irreversible monoamine oxidase B inhibitors. J Med Chem 35 3705 3713
43. PH Yu BA Davis AA Boulton 1993 Effect of structural modification of alkyl N-propargylamines on the selective inhibition of monoamine oxidase B activity. Biochem Pharmacol 46 753 757
44. P Yu BA Davis DA Durden A Barber I Terleckyj WG Nicklas AA Boulton 1994 Neurochemical and neuroprotective effects of some aliphatic propargylamines: new selective nonamphetamine-like monoamine oxidase B inhibitors. J Neurochem 62 697 704